Targeting oncogenic signaling pathways by exploiting nanotechnology

Cell Cycle

Volumn 8, Issue 21, 2009, Pages 3480-3487

  Basu, Sudipta ^a   Chaudhuri, Padmaparna ^a   Sengupta, Shiladitya ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; MAPK; Nanoparticle; Nanotechnology; Signal transduction

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; AZD 3409; BEVACIZUMAB; CYCLOSPORIN; DASATINIB; DEFOROLIMUS; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; IMATINIB; INSULIN; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; PACLITAXEL; PD 980589; PROTEIN TYROSINE KINASE; R 11577; RAPAMYCIN; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WORTMANNIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MATURATION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INHIBITION; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; NANOANALYSIS; NANOTECHNOLOGY; NONHUMAN; ONCOGENE; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 70449706006     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.21.9851     Document Type: Review

References (91)

1. http://www.cancer.org (Statistics for 2009).
2. Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med 2008; 59:251-265
3. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008; 41:98-101.
4. Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NFkappaB inhibitor DHMEQ. Curr Pharm Des 2009; 15:792-808.
5. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an Emerging Platform for Cancer Therapy. Nature Nanotech 2007; 2:751-760 (Pubitemid 350223348)
6. Ferrari M. Cancer Nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5:161-171
7. Gu F, Langer R, Farokhzad OC. Formulation/ preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol 2009; 544:589-598
8. Lee AL, Wang Y, Cheng HY, Pervaiz S, Yang YY. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 2009; 30:919-927
9. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, et al. Drug delivery with carbon nanotube for in vivo cancer treatment. Cancer Res 2008; 68:6652-6660
10. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody- targeted liposomal drugs. Cancer Res 2002; 62:7190-7194 (Pubitemid 36025236)
11. Bailey VJ, Easwaran H, Zhang Y, Griffiths E, Belinsky SA, Herman JG, et al. MS-qFRET: A quantum dot-based method for analysis of DNA methylation. Genome Res 2009; Epub ahead of print.
12. Saravanakumar G, Min KH, Min DS, Kim AY, Lee CM, Cho YW, et al. Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paxclitaxel: Synthesis, characterization and in vivo biodistribution. J Controlled Release 2009; Epub ahead of print.
13. Jin S, Leach JC, Ye K. Nanoparticle-mediated gene delivery. Methods Mol. Biol 2009; 544:547-557
14. Zhang S, Doschak MR, Uludaq H. Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine- coated albumin nanoparticle. Biomaterials 2009; Epub ahead of print.
15. Chittasupho C, Xie SX, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ. ICAM-1 targeting of doxorubicin- loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm 2009; 37:141-150
16. Schlessinger J. Cell signaling by receptor tyrosine kinase. Cell 2000; 103:211-225
17. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinase: targets for cancer therapy. Nature Rev Cancer 2004; 4:361-370 (Pubitemid 38579482)
18. Sebolt-Leopold JS, English JM. Mechanism of drug inhibition of signaling molecules. Nature 2006; 441:457-462
19. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9:1165-1172
20. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MT, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50:1550-1558 (Pubitemid 20090470)
21. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003; 348:994-1004. (Pubitemid 36302244)
22. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nature Rev Cancer 2002; 2:795-803. (Pubitemid 37328914)
23. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971; 285:1182-1186
24. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599 (Pubitemid 27441066)
25. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res 1999; 59:99-106. (Pubitemid 29062964)
26. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59:5412-5416 (Pubitemid 29526446)
27. McCormick F. Signaling networks that cause cancer. Trends Cell Biol 1999; 9:53-56
28. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4:257-262 (Pubitemid 37329790)
29. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature 2006; 441:424-430 (Pubitemid 44050136)
30. Downword J. Targeting RAS signaling pathways in cancer chemotherapy. Nat Rev Cancer 2002; 3:11-22.
31. Davies H, Begnelli GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954
32. Friday BB, Adjei AA. Advances in targeting the Ras/ Raf/MEK/Erk mitogen activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008; 14:342-346
33. Bos JL, Fearon ER, Hamilton SR, Vries MV, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutation in human colorectal cancers. Nature 1987; 327:293-297
34. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6:313-319 (Pubitemid 39361432)
35. Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Invest Drugs 2003; 4:1428-1435 (Pubitemid 38120205)
36. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx Curr Opin Invest Drugs 2003; 4:757-763
37. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18:813-822 (Pubitemid 29080340)
38. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273:18623-18632
39. Wallace E, et al. Preclinical development of ARRY- 142886, a potent and selective MEK inhibitor. Proc Annu Meet Am Assoc Cancer Res 2004; 45:3891.
40. Sengupta S, Sellers LA, Li RC, Gherardi E, Zhao G, Watson N, et al. Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation 2003; 107:2955-2961 (Pubitemid 36736639)
41. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev Drug Discov 2005; 4:988-1004.
42. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-484
43. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22.
44. LiPiccolo J, Blumenthal GM, Bernstein WD, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11:32-50.
45. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005; 8:287-297 (Pubitemid 41443414)
46. Shah RA, Khan MA. Nanopharmaceuticals: Challenges and Regulatory Perspective. De Villiers MM, Aramwit P, Kwon GS, eds. Nanotechnology in Drug Delivery. Springer NY 2009; 621-646
47. Waterman KC, Sutton SC. A computational model for particle size influence on drug absorption during controlled-release colonic delivery. J Controlled Release 2003; 86:293-304.
48. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremophor-EL-free formulation of paclitaxel. Nanomedicine 2007; 2:415-423 (Pubitemid 47365124)
49. Basaran E, Demirel M, Sirmagul B, Yazan Y. Cyclosporin-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2009; epub ahead of print.
50. Vyas SP, Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomedicine 2006; 1:417-432
51. Yang Z, Leon J, Martin M, Harder JW, Zhang R, Liang D, et al. Pharmacokinetics and biodistribution of near-infrared fluorescent polymeric nanoparticles. Nanotechnology 2009; 20:1-10.
52. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale and clinical applications, existing and potential. Int J Nanomed 2006; 1:297-315.
53. Bisht S, Feldman G, Koorstra J-BM, Mullendore M, Alvarez H, Karikari C, et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008; 7:3878-3888
54. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MNV. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 2009; 26:492-501.
55. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neuroscience 2006; 7:65-74. (Pubitemid 41828932)
56. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 6:564-569
57. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smir nova ZS, et al. Chemotherapy of gioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004; 109:759-767
58. Bonoiua AC, Mahajan SD, Ding H, Roy I, Yong K-T, Kumar R, et al. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci 2009; 106:5546-5550
59. El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 2009; 26:1752-1763
60. Sung JC, Pulliman BL, Edwards DA. Nanopartices for drug delivery to the lungs. Trends Biotehnol 2007; 25:563-570
61. Petre CE, Dittmer DP. Liposomal doxorubicin as treatment for Kaposi's sarcoma. Int J Nanomedicine 2007; 2:277-288 (Pubitemid 350047773)
62. Pereverzava E, Treschalin I, Bodyagin D, Maksimenko O, Kreuter J, Gelperina S. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicol Lett 2008; 178:9-19.
63. Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano 2009; accepted.
64. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ. Targeted single-wall carbon Nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc 2008; 130:11467-11476
65. Wang XL, Xu R, Wu X, Gillespie D, Jensen R, Lu ZR. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol Pharm 2009; 6:738-746
66. Patil ML, Zhang M, Taratula O, Garbuzenko OB, He H, Minko T. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009; 10:258-266
67. Shah N, Chaudhari K, Dantuluri P, Murthy RS, Das S. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target 2009; 17:533-542
68. Zhang H, Zeng X, Li Q, Gaillard-Kelly M, Wagner CR, Yee D. Fluorescent tumor imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore. Br J Cancer 2009; 101:71-79
69. Zhu J, Xue J, Guo Z, Zhang L, Marchant RE. Biomimetic glycoliposomes as nanocarriers for targeting P-selectin on activated platelets. Bioconj Chem 2007; 18:1366-1369 (Pubitemid 47464040)
70. Santini JT, Cima MJ, Langer RA. Controlled-release microchip. Nature 1999; 397:335-338
71. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular drugs. Bioconj Chem 2003; 14:412-419 (Pubitemid 36348665)
72. 2-Au nanoshells for controlled drug delivery. J Controlled Release 2007; 123:219-227
73. Paasonen L, Laaksonen T, Johans C, Yliperttula M, Kontturi K, Urtti A. Gold nanoparticles enable selective light-induced contents release from liposomes. J Controlled Release 2007; 122:86-91. (Pubitemid 47284557)
74. Liu KH, Liu TY, Liu DM, Chen SY. Electrical-sensitive nanoparticle composed of chitosan and tetraethyl orthosilicate for controlled drug release. J Nanosci Nanotechnol 2009; 9:1198-1203
75. Brazel CS. Magnetothermally-responsive nanomaterials: combining magnetic nanostructures and thermally- sensitive polymers for triggered drug release. Pharm Res 2009; 26:644-656
76. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Advanced Drug Deliv Rev 2001; 53:321-339
77. Huang S-L. Liposomes in ultrasonic drug and gene delivery. Advanced Drug Deliv Rev 2008; 60:1167-1176
78. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, Discher DE. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate an shrink tumors, inducing apoptosis in proportion to accumulated drug. J Controlled Release 2006; 116:150-158 (Pubitemid 44868999)
79. Sengupta S, Eavarone DA, Capila I, Zhao G, Watson N, Kiziltepe T, et al. Novel cancer therapy through temporal targeting of both tumor cells and neovasculature using a unique nanoscale delivery system. Nature 2005; 436:568-572
80. Lee H, Hu M, Reilly RM, Allen C. Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. Mol Pharm 2007; 4:769-781
81. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Rev Cancer 2009; 9:28-39.
82. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nature Chem Biol 2006; 2:689-700. (Pubitemid 44764211)
83. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci 2009; 106:7957-7961
84. Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009; (in press).
85. Jiang W, Kim BYS, Rutka JT, Chan WCW. Nanoparticle-mediated cellular response in size-dependent. Nature Nanotech 2008; 3:145-150
86. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, et al. Prodrugs: design and clinical applications. Nature Rev Drug Discov 2005; 7:255-270
87. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-7058
88. Breslin EM, White PC, Shore AM, Clement M, Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol 2005; 144:791-800. (Pubitemid 40516119)
89. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, et al. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin. Cancer Res 2005; 11:6065-6074 (Pubitemid 41170339)
90. Jasinghe VJ, Xie Z, Zhou J, Khng J, Poon LF, Senthilnathan P, et al. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol 2008; 49:985-997
91. Fujiwara M, Izuishi K, Sano T, Hossain MA, Kimura S, Masaki T, et al. Modulating effect of the PI3- kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res 2008; 27:76-84.